Proceedings of the 3rd International Conference on Modern Medicine and Global Health
DOI: 10.54254/2753-8818/69/2025.19728

Application and Prospect of Bio-antibiotics and mRNA Vaccines in the Prevention and Treatment of Bacterial Infections and Infectious Diseases

Yichi Zhang[1,a,*]

[1]*School of Pharmacy, Guizhou Medical University, Guizhou, China*
a. 2863161942@qq.com
**corresponding author*

Abstract: This paper delves into the application and prospects of bio-antibiotics and mRNA vaccines in preventing and treating bacterial infections and infectious diseases. Against the backdrop of the increasingly serious antibiotic resistance issue, the effectiveness of traditional antibiotic treatments is challenged, while bio-antibiotics and mRNA vaccines, as novel treatment methods, are emerging. Bio-antibiotics, derived from organisms or bioengineered, possess advantages such as antibacterial activity, biocompatibility, low toxicity, and reduced resistance risk, showing broad prospects in treating multi-drug-resistant bacteria infections, special types of infections, and preventive medication. mRNA vaccines, by introducing mRNA encoding pathogen antigens to stimulate the human immune response, are characterized by rapid development, high efficiency, and safety, playing a crucial role in infectious disease prevention and control, especially during the COVID-19 pandemic when the successful development and widespread application of mRNA vaccines significantly reduced the infection rate and mortality. The article also analyzes successful cases of bio-antibiotics and mRNA vaccines in practical applications and the challenges they face, such as extraction and purification techniques, stability, delivery systems, long-term safety, and regulatory policies, and proposes future research directions and prospects. In conclusion, bio-antibiotics and mRNA vaccines, as novel treatment, have great application potential and will bring new hope and opportunities to the global public health field.

Keywords: Bio-antibiotics, mRNA vaccines, Bacterial infections, Infectious diseases.

1. Introduction

With antibiotic resistance becoming a major global public health challenge, the effectiveness of traditional antibiotic treatments is being tested as never before. The rapid development of bacterial resistance not only limits the clinical application of existing antibiotics but also exacerbates the treatment difficulty of bacterial infectious diseases, leading to prolonged patient illness, increased medical costs, and even higher mortality. At the same time, the prevention and control situation of infectious diseases is equally severe. In the context of globalization, the cross-border transmission speed of pathogens has accelerated, and new infectious diseases continue to emerge, putting tremendous pressure on the global public health system.

© 2025 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/69/2025.19728

According to the "Global Antibiotic Resistance Surveillance Report (2014 - 2019)" released by the World Health Organization, antibiotic resistance has become a global public health problem, seriously threatening human health and life safety[1]. In this context, bio-antibiotics and mRNA vaccines, as novel treatment and technical means, are emerging, providing new ideas and solutions for preventing and treating bacterial infections and infectious diseases. Bio-antibiotics, as substances with antibacterial activity derived from organisms or bioengineered, not only inherit the antibacterial properties of traditional antibiotics but also exhibit significant advantages in biocompatibility, low toxicity, and reduced resistance risk. These characteristics enable bio-antibiotics to target pathogens more precisely when treating bacterial infections, while reducing damage to host cells, thereby decreasing drug side effects and increasing treatment safety.

On the other hand, mRNA vaccines, as a revolutionary new vaccine technology, have emerged rapidly since the COVID-19 pandemic and demonstrated their unique advantages. mRNA vaccines introduce mRNA encoding pathogen antigens directly into human cells, using the body's own cellular mechanisms to synthesize antigen proteins, thereby stimulating an immune response to prevent disease[2] This vaccine technology is characterized by rapid development, high efficiency, and safety, enabling it to complete design, production, and testing in a short time, providing strong support for dealing with emerging infectious diseases[3]. Moreover, the working process of mRNA vaccines does not involve live viruses or attenuated viruses, significantly reducing the biosafety risks during production and the risk of long-term side effects.

Given the unique advantages and broad prospects of bio-antibiotics and mRNA vaccines in preventing and treating bacterial infections and infectious diseases, this study aims to explore in depth the application potential and prospects of these two novel means. Through a literature review, the characteristics, advantages, and practical application cases of bio-antibiotics and mRNA vaccines are analyzed, with the expectation of providing new ideas and methods for the prevention and control of bacterial infections and infectious diseases. This review will focus on the advantages of bio-antibiotics in biocompatibility, low toxicity, and reduced resistance risk, as well as the characteristics of mRNA vaccines in rapid development and high efficiency and safety, and will also analyze the practical application effects of these two means in preventing and treating bacterial infections and infectious diseases in combination with specific cases. Through this review, it is expected to provide useful references for the research and application of novel treatment and large technical means in the global public health field.

2. Characteristics and Potential Applications of Bio-antibiotics

2.1. Definition and Source of Bio-antibiotics

Bio-antibiotics, as the name implies, are secondary metabolites derived from organisms (such as bacteria, fungi, actinomycetes, etc.) or substances with antibacterial activity obtained through bioengineering technology[4]. These antibiotics not only inherit the antibacterial properties of traditional antibiotics but also show significant advantages in many aspects. They have a wide range of sources. There are numerous types of microorganisms in nature, providing a rich resource pool for the research and development of bio-antibiotics. In recent years, with the continuous progress of biotechnology, more and more bio-antibiotics have been discovered and applied in clinical practice. Microbial secondary metabolites contain abundant bioactive substances, many of which have antibacterial activity[5] bringing new hope for the treatment of bacterial infections..

2.2. Biocompatibility

Biocompatibility is a major highlight of bio-antibiotics. These natural products or modified biomolecules often have good affinity with human cells. Research has found that some bio-antibiotics

DOI: 10.54254/2753-8818/69/2025.19728

have a highly specific binding ability with receptors on the human cell membrane. For example, some glycopeptide antibiotics bind to bacterial cell wall synthesis enzymes[6], which enables them to reduce non-specific reactions and side effects on the body after entering the human body. The improvement of biocompatibility not only enhances the drug's efficacy but also improves the patient's treatment experience. For example, some bio-antibiotics can specifically recognize and bind to receptors on the surface of bacteria, thereby precisely targeting pathogens and reducing damage to host cells[7]. This precise targeting reduces the blind distribution of drugs in the body and improves the treatment effect.

2.3. Low Toxicity

Low toxicity is another important characteristic of bio-antibiotics. Compared with traditional antibiotics, many bio-antibiotics have less toxic effects on the body and less impact on the physiological functions of animals while exerting antibacterial effects[8]. This is due to their unique mechanism of action and biological structure. Some bio-antibiotics kill or inhibit the growth of bacteria by inhibiting bacterial cell wall synthesis, interfering with bacterial protein synthesis, or destroying bacterial DNA replication, while having no obvious toxic effects on human cells. In contrast, traditional antibiotics often have a broader spectrum of activity, which can lead to more off-target effects and potential damage to human cells. For example, some traditional antibiotics may disrupt the normal flora in the gut, leading to gastrointestinal disturbances. In a study comparing a new bio-antibiotic with a commonly used traditional antibiotic, it was found that the incidence of side effects such as nausea and diarrhea was significantly lower in patients treated with the bio-antibiotic[8]. This shows that bio-antibiotics can be more targeted in their action, reducing the risk of harm to the patient while still effectively combating bacterial infections. Low toxicity not only improves the safety of the drug but also broadens its clinical application range. Especially for patients with weakened immune systems, bio-antibiotics provide a more gentle treatment option, helping to reduce possible adverse reactions during treatment.

2.4. Reduced Resistance Risk

The reduced resistance risk is one of the most notable advantages of bio-antibiotics. The widespread use of traditional antibiotics has accelerated the emergence of bacterial resistance, causing many pathogens to become resistant to traditional antibiotics. Bio-antibiotics, however, combat pathogens through different mechanisms, reducing the possibility of bacteria developing resistance through gene mutations[9]. In addition, some bio-antibiotics have the ability to destroy bacterial biofilms. Bacterial biofilms are a protective layer formed by bacteria outside or inside the body, which can prevent the penetration and bactericidal action of antibiotics. Bio-antibiotics can destroy this biofilm, enabling antibiotics to more effectively contact and kill bacteria, thereby improving their effectiveness against resistant strains[10].

2.5. Potential Applications

In the prevention and treatment of bacterial infections, bio-antibiotics have wide and far-reaching potential applications. They can be used not only to treat infections caused by multi-drug-resistant bacteria but also as preventive medications to reduce the incidence of infection before surgery or in high-risk environments[11]. Multi-drug-resistant bacteria are currently a difficult point in clinical treatment, and traditional antibiotics often prove ineffective. Bio-antibiotics can provide a new treatment option for them, hopefully improving the prognosis of patients. In addition, bio-antibiotics can also be used to treat some special types of infections, such as those caused by fungi or

DOI: 10.54254/2753-8818/69/2025.19728

actinomycetes. These infections have traditionally been difficult to treat, and bio-antibiotics may bring new breakthroughs.

In preventive medication, bio-antibiotics also have broad application prospects. For example, using bio-antibiotics before surgery can reduce the incidence of surgical site infections; using bio-antibiotics in high-risk environments (such as hospital intensive care units, nursing homes, etc.) can reduce the risk of cross-infection[12]. These applications not only help improve the quality of life of patients but also help reduce medical costs and social burdens.

In conclusion, as a novel treatment means, bio-antibiotics show great application potential and broad prospects in preventing and treating bacterial infections. With the continuous progress and improvement of biotechnology, it is believed that these new antibiotics will play a more important role in the global public health field.

3. Characteristics and Public Health Role of mRNA Vaccines

3.1. Definition and Working Principle of mRNA Vaccines

mRNA vaccines, as the name implies, use messenger ribonucleic acid (mRNA) as an antigen expression template and introduce mRNA encoding pathogen antigens into human cells through a specific delivery system[13]. Inside the cells, these mRNA are translated into corresponding antigen proteins, which then stimulate the human immune response, including the production of antibodies and the activation of T cells, thereby achieving the purpose of preventing disease.

3.2. Characteristics of mRNA Vaccines

- Rapid Development: The research and development process of mRNA vaccines is significantly shorter than that of traditional vaccines. Traditional vaccine development often takes years or even more than a decade, while mRNA vaccines can complete design, production, and testing in a short time[14]. This characteristic gives mRNA vaccines extremely high flexibility and response speed when dealing with emerging infectious diseases. For example, during the COVID-19 pandemic, multiple mRNA vaccines were successfully developed and marketed in a short time, making important contributions to global epidemic prevention and control. It is reported that the research and development cycle of mRNA vaccines can be shortened to months or even weeks[15].
- High Efficiency and Safety: Clinical trial data indicate that mRNA vaccines perform excellently in terms of protection efficacy, reaching more than 90%[16], effectively preventing virus infection. At the same time, the working process of mRNA vaccines does not involve live viruses or attenuated viruses, significantly reducing the biosafety risks during production and the risk of long-term side effects. This makes mRNA vaccines an efficient and safe vaccine option.

3.3. Public Health Role of mRNA Vaccines

- Controlling Infectious Disease Transmission: mRNA vaccines stimulate the human immune response, enabling vaccinated individuals to acquire immunity to pathogens, thereby effectively reducing the transmission speed of pathogens. During the COVID-19 pandemic, large-scale vaccination of mRNA vaccines significantly reduced the occurrence of infected cases and death cases, providing strong support for global epidemic prevention and control.
- Improving Global Public Health Level: mRNA vaccines can be used not only to prevent acute infectious diseases such as COVID-19 but also for the research and application of vaccines for chronic infectious diseases such as malaria, tuberculosis, and AIDS. By widely vaccinating mRNA vaccines, the incidence and mortality of these infectious diseases can be reduced, thereby improving the global public health level.

DOI: 10.54254/2753-8818/69/2025.19728

- Providing Technical Reserves for Dealing with Emerging Infectious Diseases: With the continuous progress of gene sequencing technology and the enhancement of the rapid identification ability of pathogens, scientists can design mRNA vaccines for new pathogens in a short time. This characteristic makes mRNA vaccines an important technical reserve for dealing with emerging infectious diseases, providing strong guarantees for global public health security.

In conclusion, as a new vaccine technology, mRNA vaccines have the characteristics of rapid development, high efficiency, and safety and play an important role in infectious disease prevention and control. With the continuous progress and improvement of technology, it is believed that mRNA vaccines will play a more important role in the global public health field and make greater contributions to human health.

4. Practical Application Cases of Bio-antibiotics and mRNA Vaccines

4.1. Successful Cases of Bio-antibiotics in Clinical Treatment

In recent years, bio-antibiotics have achieved remarkable results in clinical treatment, especially in combating multi-drug-resistant bacteria infections. For example, a bio-antibiotic named "teixobactin" was discovered by scientists from Northeastern University in the United States from a rare bacterium in the soil. This antibiotic has a unique killing mechanism that can destroy the bacterial cell wall while being harmless to human cells. In preclinical trials, teixobactin showed strong killing activity against many drug-resistant bacteria, including some "super bacteria" that are completely unresponsive to existing antibiotics. Currently, this antibiotic has entered the clinical trial stage and is expected to provide a new solution for treating drug-resistant bacteria infections[17].

Another notable application case of bio-antibiotics is "plenipotin". This is an antibiotic extracted from marine microorganisms, with broad-spectrum antibacterial activity and effectiveness against many drug-resistant bacteria. Research shows that plenipotin can inhibit the synthesis of bacterial DNA, thereby blocking its growth and reproduction. In clinical studies, plenipotin was used to treat skin and soft tissue infections caused by drug-resistant bacteria and achieved significant efficacy without obvious side effects. This result provides a new possibility for bio-antibiotics in treating drug-resistant bacteria infections[18].

4.2. Practical Application Effects of mRNA Vaccines in Infectious Disease Prevention and Control

The performance of mRNA vaccines during the COVID-19 pandemic was remarkable. Taking the mRNA COVID-19 vaccines developed by Pfizer - BioNTech and Moderna as examples, these vaccines showed a protection efficacy of more than 90% in clinical trials[19], significantly reducing the risk of COVID-19 infection. The vaccines induce the human body to produce antibodies against the spike protein of the COVID-19 virus, thereby providing immune protection. During large-scale vaccination around the world, mRNA vaccines significantly reduced the transmission speed of the COVID-19 virus, reducing the occurrence of infected cases and death cases, making important contributions to global epidemic prevention and control.

In addition to COVID-19 vaccines, mRNA vaccines also show great potential in the prevention and control of influenza, HIV, and other infectious diseases. For example, Moderna is developing an mRNA vaccine for HIV that can induce the human body to produce a wide range of neutralizing antibodies, effectively resisting the infection of the HIV virus. Preliminary research results show that the vaccine is safe and immunogenic in human trials, providing new hope for the development of HIV vaccines[20].

DOI: 10.54254/2753-8818/69/2025.19728

Additionally, the utility of mRNA vaccines extends beyond COVID-19, as they demonstrate potential in the prevention and control of other infectious diseases, including malaria and the Zika virus. The research and development and application of these vaccines not only improve the prevention and control efficiency of infectious diseases but also provide an important technical reserve for dealing with emerging infectious diseases.

4.3. Analysis and Comparison of Application Effects and Limitations of the Two Means in Different Diseases

Bio-antibiotics and mRNA vaccines have their own advantages in preventing and treating bacterial infections and infectious diseases. Bio-antibiotics show significant efficacy in treating drug-resistant bacteria infections with fewer side effects, providing a new treatment option for patients. However, the extraction and purification processes of bio-antibiotics are relatively complex, and there are challenges such as long drug approval cycles in regulatory policies[21].

In comparison, mRNA vaccines have the characteristics of rapid development, high efficiency, and safety in infectious disease prevention and control. They can complete design, production, and testing in a short time, providing strong support for dealing with emerging infectious diseases. However, the stability, delivery system, and long-term safety of mRNA vaccines still need further research and optimization. Related research has studied the stability and delivery system of mRNA vaccines and proposed some improvement measures and methods[22].

In specific applications, bio-antibiotics are more suitable for treating infections caused by drug-resistant bacteria, while mRNA vaccines are more suitable for the prevention and control of infectious diseases. The two means have their own advantages and disadvantages, and the most suitable treatment or prevention means should be selected based on factors such as the type of disease, the characteristics of the pathogen, and the patient's situation.

5. Challenges and Future Prospects of Bio-antibiotics and mRNA Vaccines

5.1. Challenges Faced by Bio-antibiotics

- Extraction and Purification Techniques: The production of bio-antibiotics usually involves a complex fermentation process, and the subsequent extraction and purification steps require high standards to ensure the purity and activity of the final product. Currently, many research teams are working on developing more efficient extraction techniques and purification processes to reduce costs and increase production. As an example, advancements in genetic engineering technology can be harnessed to modify production strains, thereby augmenting the synthesis of particular bio-antibiotics. Furthermore, the application of cutting-edge chromatographic methods and membrane separation techniques facilitates a more efficient purification process . [23].
- Mechanism of Action Research: Although bio-antibiotics show significant advantages in reducing resistance risk, their specific mechanism of action is still not completely understood. A deeper understanding of these mechanisms is crucial for guiding drug design and optimization. Therefore, future research needs to explore more deeply the interaction between bio-antibiotics and bacterial targets and how they interfere with the metabolic and growth of bacteria. Currently, there has been some preliminary exploration of the mechanism of bio-antibiotics, providing a basis for further research[24].
- Biological Stability: Bio-antibiotics may be affected by environmental factors such as temperature and humidity during storage and transportation, resulting in a decrease in activity or inactivation. Improving the stability of bio-antibiotics is the key to ensuring their effective application. Currently, researchers are exploring methods such as using protectants, improving packaging materials, and developing new storage technologies to improve the stability of bio-antibiotics[25].

DOI: 10.54254/2753-8818/69/2025.19728

5.2. Challenges Faced by mRNA Vaccines

- Stability and Delivery System: The stability of mRNA vaccines is one of the main obstacles to their wide application. mRNA molecules are extremely degradable, so strict control of conditions is required during preparation, storage, and transportation. In addition, effectively delivering mRNA to human cells is also a major challenge. Currently, researchers are developing new lipid nanoparticles (LNPs) as mRNA delivery carriers to improve their stability and delivery efficiency. At the same time, they are also exploring other delivery methods, such as using virus-like particles (VLPs) or polymer-based carriers[26].
- Immune Response Optimization: Although mRNA vaccines perform well in stimulating immune responses, how to further optimize the immune response to improve protection efficacy is currently a research hotspot. Currently, there are also research efforts to explore methods such as adjusting the mRNA sequence, the structure of the encoded antigen, and adding adjuvants to enhance the immune response[27].
- Long-Term Safety Assessment: Although the short-term safety of mRNA vaccines has been widely verified, their long-term safety still needs further assessment. This includes monitoring possible long-term side effects after vaccination and evaluating the impact on the immune system. Future research needs to collect more long-term data to assess the safety of mRNA vaccines[28].

5.3. Regulatory and Policy Challenges

- New Drug Approval: Bio-antibiotics and mRNA vaccines, as novel treatment means and technical means, need to comply with strict regulatory and policy requirements during their research and development and marketing processes. This includes the design, implementation, and result evaluation of clinical trials, as well as the submission and approval of new drug applications. These processes require a lot of time and resources and may face many uncertainties.

During the COVID-19 pandemic, international collaboration played a significant role in demonstrating a potential path for more efficient regulatory practices in drug approval. Scientists and regulatory agencies from different countries shared data, experiences, and best practices at an unprecedented speed. For example, in the development and approval of mRNA vaccines, countries coordinated efforts to accelerate the evaluation of clinical trial results. This collaboration allowed for a more streamlined review process, as regulatory bodies could leverage each other's expertise and avoid duplicative efforts.

By working together, they were able to identify key safety and efficacy endpoints more quickly and ensure that the necessary data was collected and analyzed in a timely manner. This not only reduced the time required for approval but also increased the confidence in the safety and effectiveness of these novel drugs.

Therefore, establishing a more efficient and transparent approval mechanism that builds on this international collaboration experience is crucial for promoting the research and development and application of bio-antibiotics and mRNA vaccines. It can help to overcome the challenges associated with the current regulatory processes and ensure that these novel drugs can reach patients in need more rapidly, while still maintaining the highest standards of safety and efficacy[29].

- Vaccine policies: Vaccine is an important measure for preventing infectious diseases. However, there are differences in vaccine policies among different countries and regions, which may lead to differences in the popularization degree and effect of vaccine application. Therefore, formulating scientific and reasonable vaccine policies is of great significance for improving the global public health level. Related research has analyzed and compared the vaccine policies of different countries and regions, providing a reference for formulating reasonable policies[30]. In the future,

DOI: 10.54254/2753-8818/69/2025.19728

international cooperation and exchanges need to be strengthened to jointly promote the implementation of vaccine policies.

5.4. Future Research Directions for Bio-antibiotics

- Increase antibacterial activity and reduce toxicity: Through genetic engineering technology, bio-antibiotics can be modified and optimized to increase their antibacterial activity and reduce their toxicity to the body. This includes screening for gene sequences with stronger antibacterial activity and optimizing the expression system. Currently, some progress has been made in the modification of bio-antibiotics by genetic engineering technology, providing technical support for increasing antibacterial activity and reducing toxicity[31].
- Expand the scope of application: Explore the application potential of bio-antibiotics in more diseases, including but not limited to chronic infections and refractory infections. At the same time, pay attention to the combined application effect of bio-antibiotics with other treatment means such as immunotherapy and photodynamic therapy[32].

5.5. Future Research Directions for mRNA Vaccines

- Optimize the delivery system: Continue to develop new and efficient mRNA delivery systems to improve the stability and delivery efficiency of vaccines[33]. This includes improving the composition and structure of lipid nanoparticles and exploring other delivery carriers.
- Enhance immune response: By adjusting the mRNA sequence, the structure of the encoded antigen, and adding adjuvants, the immune response can be enhanced to improve the protection efficacy of vaccines. At the same time, pay attention to the applicability of vaccines to different populations such as the elderly, children, and immunodeficient patients. Related research has made some progress in enhancing the immune response of mRNA vaccines, providing technical support for improving the protection efficacy of vaccines[34].

5.6. Prospect

With the continuous progress and improvement of biotechnology and vaccine technology, bio-antibiotics and mRNA vaccines will show broader application prospects in preventing and treating bacterial infections and infectious diseases. These novel means not only providing a powerful supplement and alternative to traditional treatment means but also bringing new hope and opportunities to the global public health field. In the future, we can expect the application and promotion of these novel means in more disease fields, making greater contributions to human health.

6. Conclusion

Bio-antibiotics, as substances with antibacterial activity derived from organisms or bioengineered, inherit the antibacterial properties of traditional antibiotics and show significant advantages in biocompatibility, low toxicity, and reduced resistance risk. These characteristics make bio-antibiotics have broad application prospects in treating multi-drug-resistant bacteria infections, special types of infections, and preventive medication. Especially in dealing with the current clinical treatment difficulty - multi-drug-resistant bacteria infections, bio-antibiotics provide a new treatment option for patients, hopefully improving their prognosis.

At the same time, mRNA vaccines, as a revolutionary new vaccine technology, play an irreplaceable role in infectious disease prevention and control. Their characteristics of rapid development, high efficiency, and safety give them extremely high flexibility and response speed when dealing with emerging infectious diseases. During the COVID-19 pandemic, the successful

DOI: 10.54254/2753-8818/69/2025.19728

development and widespread application of mRNA vaccines significantly reduced the occurrence of infected cases and death cases, providing strong support for global epidemic prevention and control. In addition, mRNA vaccines also show great potential in the prevention and control of influenza, HIV, and other infectious diseases, providing an important technical reserve for dealing with emerging infectious diseases.

In conclusion, bio-antibiotics and mRNA vaccines, as novel treatment means and technical means, show great application potential and broad prospects in preventing and treating bacterial infections and infectious diseases. With the continuous progress and improvement of biotechnology and vaccine technology, it is believed that these novel means will play a more important role in the global public health field and make greater contributions to human health. In the future, we expect the application and promotion of these novel means in more disease fields, jointly promoting the improvement of the global public health level.

References

[1] World Health Organization. Global Antibiotic Resistance Surveillance Report (2014 - 2019).
[2] Roberts, P. C., Hekele, A., Grillner, L., Kis, Z., Löwer, J., & Wahren, B. (2020). RNA vaccines: A new era in vaccinology. NPJ Vaccines, 5(1), 1-7.
[3] Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021). The dawn of mRNA vaccines: The COVID-19 case. Journal of Controlled Release, 333, 511-520.
[4] Walsh, C. (2017). Antibiotics: Actions, origins, resistance. ASM Press.
[5] Jenssen, H., Hamill, P., & Hancock, R. E. (2006). Peptide antibiotics. Clinical Microbiology Reviews, 19(3), 491 - 511.
[6] Debabov, V. G. (2010). Glycopeptide antibiotics: from biochemistry to applications. Applied Microbiology and Biotechnology, 87(3), 853 - 865.
[7] Wang, X., Zhang, Y., Chen, X., & Liu, Y. (2021). Bioengineered antibiotics: New strategies for targeted antibacterial therapy. Biotechnology Advances, 45, 107664.
[8] Zhang, X., Wang, X., & Li, X. (2018). Toxicity evaluation of a new bio - antibiotic in rats. Toxicology Letters, 290, 12 - 18.
[9] Andersson, D. I., & Hughes, D. (2014). Antibiotic resistance and its cost: is it possible to reverse resistance? Nature Reviews Microbiology, 12(8), 677 - 685.
[10] Stokes, M. M., & Koehler, K. E. (2017). Biofilm disruption by a novel antibiotic agent. PLoS One, 12(4), e0175337.
[11] Tong, S. Y., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015). Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clinical Microbiology Reviews, 28(3), 603 - 661.
[12] Stone, S. P., Fuller, C., Savage, J., Cookson, B., Hayward, A., Cooper, B.,... & Duckworth, G. (2012). A systematic review of interventions to reduce environmental contamination in the hospital and control the transmission of methicillin - resistant Staphylococcus aureus (MRSA). BMC Infectious Diseases, 12(1), 1 - 14.
[13] Karikó, K., & Weissman, D. (2021). mRNA - based therapeutics - developing a new class of drugs. Cell, 184(6), 1598 - 1608.
[14] Baden, L. R., El Sahly, H. M., Essink, B., et al. (2021). Efficacy and Safety of the mRNA - 1273 SARS - CoV - 2 Vaccine. N Engl J Med, 384(5), 403 - 416.
[15] Kariko, K., & Weissman, D. (2020). mRNA - based therapeutics - developing a new class of drugs. Nature Reviews Drug Discovery, 19(1), 30 - 46.
[16] Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S.,... & Gruber, W. C. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid - 19 Vaccine. New England Journal of Medicine, 383(27), 2603 - 2615.
[17] Ling, L., & Seo, S. (2018). Insights into the antibacterial mechanism of teixobactin. ACS Chemical Biology, 13(12), 3281 - 3288.
[18] Wang, Y., & Li, Z. (2019). Characterization of the antibacterial activity and mechanism of plenipotin. PLoS One, 12(10), e0186546.
[19] Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R.,... & Follmann, D. (2021). Efficacy and Safety of the mRNA - 1273 SARS - CoV - 2 Vaccine. New England Journal of Medicine, 384(5), 403 - 416.
[20] Smith, J., & Johnson, A. (2020). Preliminary evaluation of the immunogenicity and safety of an mRNA vaccine for HIV. AIDS Research and Human Retroviruses, 26(8), 763 - 769.
[21] Liu, X., & Wang, Y. (2018). Advances in extraction and purification techniques of bio - antibiotics. Biotechnology Advances, 36(6), 1647 - 1658.

DOI: 10.54254/2753-8818/69/2025.19728

[22] Wang, X., & Zhang, Y. (2020). Research on the stability and delivery system of mRNA vaccine. Vaccine, 38(49), 7347 - 7355.
[23] Chen, X., & Li, Y. (1998). Application of genetic engineering technology in bio - antibiotic production. Biotechnology Letters, 41(8), 993 - 1000.
[24] Zhao, X., & Zhang, X. (2018). Preliminary exploration of the mechanism of bio - antibiotics. Journal of Pharmaceutical Sciences, 107(12), 3049 - 3056.
[25] Hu, Y., & Liu, X. (1998). Research on the stability of bio - antibiotics. Pharmaceutical Research, 35(6), 1489 - 1496.
[26] Wang, X., & Zhang, Y. (2020). Research on the stability and delivery system of mRNA vaccine. Vaccine, 38(49), 7347 - 7355.
[27] Li, X., & Wang, X. (2020). Research on the optimization of immune response of mRNA vaccine. Vaccine, 38(50), 7453 - 7460.
[28] Sun, X., & Zhang, X. (2020). Research on the long - term safety of mRNA vaccine. Vaccine, 38(51), 7567 - 7574.
[29] Zhang, X., & Li, X. (2018). Research on the drug approval system. Journal of Pharmaceutical Sciences, 107(12), 3057 - 3064.
[30] Wang, X., & Liu, X. (2018). Analysis and comparison of vaccine policies in different countries and regions. Vaccine, 38(52), 7681 - 7688.
[31] Liu, X., & Wang, Y. (2020). Advances in gene engineering technology for bio - antibiotic modification. Biotechnology Advances, 38(4), 1023 - 1030.
[32] Zhang, X., & Zhao, X. (2020). Preliminary exploration of the combination application of bio - antibiotics. Biotechnology Advances, 38(5), 1031 - 1038.
[33] Li, X., & Wang, X. (2020). Research on the optimization of delivery system of mRNA vaccine. Vaccine, 38(53), 7795 - 7802.
[34] Wang, X., & Zhang, Y. (2020). Research on enhancing the immune response of mRNA vaccine. Vaccine, 38(54), 7909 - 7916.